By Kevin Madagan
Carlyle (NASDAQ: CG) and SK Capital Partners will acquire bluebird bio (NASDAQ: BLUE), according to a news release.
bluebird, founded in 2010 and based in Somerville, Massachusetts, is a gene therapy maker.
Carlyle, with its U.S. headquarters in Washington, D.C., is a global investment firm that deploys private capital across three business segments: global private equity, global credit and investment solutions. Founded in 1987, the firm targets companies in healthcare and many other industries.
SK Capital, founded in 2007 and based in New York, is a private equity firm focused on the life sciences and a few other sectors. The firm typically pursues control buyouts, recapitalizations and growth equity investments.
Carlyle and SK Capital are taking bluebird private. News reports stated the deal values the company at around $29 million.